This paper discusses alternative incentive mechanisms for encouraging pharmaceutical innovations that support global health policy priorities. Patent buyouts, in which a public fund pays a mark-up on private valuations from sealed-bid second-price auctions, would boost the efficiency of research...

This paper develops a real options approach to the optimal sequencing of antiretroviral drug cocktails for HIV/AIDS patients in resource-poor settings. The analysis focuses on the implications of endogenous resistance mutations in the virus that reduce or eliminate the effectiveness of...

Based on the aggregation of individual willingness-to-pay for a statistical life, we calibrate an intertemporal optimization model to determine the aggregate welfare losses from HIV/AIDS in 25 Eastern European countries. Assuming a discount rate of three percent, we find a total welfare loss for...

Based on the aggregation of individual willingness-to-pay for a statistical life, we calibrate an intertemporal optimization model to determine the aggregate welfare losses from HIV/AIDS in 25 Eastern European countries. Assuming a discount rate of three percent, we find a total welfare loss for...

This paper discusses alternative incentive mechanisms for encouraging pharmaceutical innovations that support global health policy priorities. Patent buyouts, in which a public fund pays a mark-up on private valuations from sealed-bid second-price auctions, would boost the efficiency of research...

This paper develops a real options approach to the optimal sequencing of antiretroviral drug cocktails for HIV/AIDS patients in resource-poor settings. The analysis focuses on the implications of endogenous resistance mutations in the virus that reduce or eliminate the effectiveness of...